Compare ADMA Biologics Inc (ADMA) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Ryanair Holdings plc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Ryanair Holdings plc trades at $65.74 (market cap $32.49B). The key difference: Ryanair Holdings plc is far larger — about 15.3× ADMA Biologics Inc's market cap, and Ryanair Holdings plc pays a 1.49% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | RYAAY | |
|---|---|---|
Market Cap | $2.13B | $32.49B |
Sector | Health | Industrials |
52-Week High | $20.38 | $73.82 |
52-Week Low | $7.60 | $53.24 |
Enterprise Value | $2.20B | $30.15B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Ryanair Holdings (RYAAY) trades at $66.35, up 1.31% with bullish technical signals from moving averages. The company demonstrates strong fundamentals with a P/E of 14.42, net income margin of 13.98%, and consistent earnings beats. Recent traffic growth of 7% in June 2026 and improved family seating policy reflect operational strength. Cash flow from operations remains robust at $3.42B despite negative net cash flow of -$12M in 2025.
RYAAY presents a compelling investment case with analyst consensus favoring Buy (62.5%) and bullish technical indicators. The airline's debt-free balance sheet, 80% fuel hedge for 2027, and cost leadership provide competitive advantages. Key risks include rising operating costs, macroeconomic uncertainty, and potential regulatory pressures. The stock's current valuation appears reasonable given strong profitability metrics and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
